Curaleaf Launches Hostile Bid for Aurora Cannabis, Shareholders to Decide Fate

Curaleaf Holdings Inc., a major U.S. cannabis operator, has made an unsolicited bid to acquire Aurora Cannabis Inc., prompting the Canadian firm to form a special committee to evaluate the proposal. The move comes after Curaleaf's repeated private overtures were rebuffed by Aurora's board, leading Curaleaf to take its offer directly to shareholders. If successful, the acquisition would create a cannabis powerhouse operating in 17 countries across Europe, North America, and other international markets

Curaleaf’s CEO Boris Jordan expressed frustration with Aurora’s leadership, stating, “We were very disappointed that the board refused to meaningfully engage.” He added, “We will now take our proposal directly to Aurora shareholders because the premium is significant, the strategic rationale is compelling, and further delay is unjustified.” According to Curaleaf, the deal would offer Aurora shareholders US$4.00 per share plus US$0.75 in cash per share, and could generate at least US$40 million in annual cost synergies

Aurora acknowledged receiving Curaleaf’s proposals, including letters sent on June 23 and July 7, but disputed claims of non-engagement. Aurora said its lead independent director had corresponded with Curaleaf’s CEO as recently as July 24, emphasizing that the company remains focused on its current business plan and is open to ongoing dialogue. Aurora’s response urged shareholders not to take any action yet and stated that it would only make further public comments if necessary by law or in the best interests of shareholders

Market analysts have weighed in, with TD Cowen’s Derek Lessard and Ryan Neal arguing that Curaleaf’s offer “undervalues the long-term potential of Aurora’s business.” They highlighted Aurora’s leadership in medical cannabis and its strong international presence as key drivers of future value. Meanwhile, Curaleaf maintains that the merger would “unlock value” by combining its global distribution with Aurora’s cultivation and manufacturing strengths, noting that the two companies generated more than US$1.5 billion in revenue over the past year

OG Lab notes that this high-profile bid signals intensifying consolidation in the global cannabis industry, with major players seeking scale and international reach. The outcome will likely influence future cross-border cannabis mergers and could reshape competitive dynamics in both North American and European markets